Results 121 to 130 of about 40,710 (290)

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Direct methylation of FXR by Set7/9, a lysine methyltransferase, regulates the expression of FXR target genes

American Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
The farnesoid X receptor (FXR) is a ligand (bile acid)-dependent nuclear receptor that regulates target genes involved in every aspect of bile acid homeostasis. Upon binding of ligand, FXR recruits an array of coactivators and associated proteins, some of which have intrinsic enzymatic activity that modify histones or even components of the ...
Natarajan, Balasubramaniyan, Meena, Ananthanarayanan, Frederick J, Suchy   +2 more
openaire   +3 more sources

Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis

Portal Hypertension &Cirrhosis, EarlyView.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao, Sheng Cheng, Qiaoling Pan, Jiong Yu, Hongcui Cao   +4 more
wiley   +1 more source

Farnesoid X Receptor as a potential protein target for mushroom LMW compounds: virtual screening using molecular docking [PDF]

, 2017
Farnesoid X receptor (FXR) is a nuclear receptor protein involved in controlling several metabolic pathways, with bile acids as his natural ligands. FXR functions as a sensor for bile acids, thus promoting their clearance by controlling expression of ...
Abreu, Rui M.V., Ferreira, Isabel C.F.R.
core  

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source

Allosteric modulation of the farnesoid X receptor by a small molecule

Scientific Reports, 2018
The bile acid activated transcription factor farnesoid X receptor (FXR) regulates numerous metabolic processes and is a rising target for the treatment of hepatic and metabolic disorders.
Matthias Gabler, Jan Kramer, Jurema Schmidt, Julius Pollinger, Julia Weber, Astrid Kaiser, Frank Löhr, Ewgenij Proschak, Manfred Schubert-Zsilavecz, Daniel Merk   +9 more
doaj   +1 more source

Phytochemicals in MASLD: A Focused Review of Gut Microbiome‐Linked Mechanisms

Phytotherapy Research, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as a major global health burden, yet effective pharmacological options remain limited. Recent advances highlight the gut microbiome as a key modulator of liver metabolism, inflammation, and fibrosis, making it a promising therapeutic target.
Jeong In Seo, Su Min Kim, Hye Hyun Yoo
wiley   +1 more source

Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding.

PLoS ONE, 2012
Farnesoid X receptor (FXR) is a nuclear receptor and a key regulator of liver cholesterol and triglyceride homeostasis. Scavenger receptor class B type I (SR-BI) is critical for reverse cholesterol transport (RCT) by transporting high-density lipoprotein
Guodong Li, Ann M Thomas, Jessica A Williams, Bo Kong, Jie Liu, Yuka Inaba, Wen Xie, Grace L Guo   +7 more
doaj   +1 more source

Ursodeoxycholic acid acts as an ileal FXR agonist in male mice with hepatic deficiency of FXR

eGastroenterology
Background Farnesoid X receptor (FXR) has been identified as a therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH). Hepatic FXR is especially critical in suppressing liver inflammation. FXR agonism and antagonism have both proven to be beneficial in the mitigation of MASH, leading to much ...
Zakiyah R Henry, Syeda Maliha, Veronia Basaly, Zhenning Yang, Rulaiha E Taylor, Katherine Otersen, Vik Meadows, Daniel Rizzolo, Mary Stofan, Anisha Bhattacharya, Peihong Zhou, Anita Brinker, Ill Yang, Lanjing Zhang, Laurie B Joseph, Brian Buckley, Bo Kong, Grace L Guo   +17 more
openaire   +2 more sources

Farnesoid X receptor prevents hyperuricemia via activating ATP‐binding cassette subfamily G member 2

Rheumatology &Autoimmunity, EarlyView.
Farnesoid X receptor (FXR) activation reduces serum uric acid levels by upregulating the intestinal urate transporter ATP‐binding cassette subfamily G member 2 (ABCG2). These findings uncover a novel metabolic pathway for urate excretion and suggest that FXR agonists (e.g., obeticholic acid), represent a promising therapeutic strategy for the treatment
Rui Li, Guo Tang, Ye Yu, Guang‐Liang Chen, Liangjing Lu, Juan Wang   +5 more
wiley   +1 more source